急性髓系白血病 - Suppr

Suppr

超能文献

Acute myeloid leukemia.

作者信息

Löwenberg B, Downing J R, Burnett A

机构信息

Department of Hematology, Erasmus University and University Hospital Rotterdam, The Netherlands.

出版信息

N Engl J Med. 1999 Sep 30;341(14):1051-62. doi: 10.1056/NEJM199909303411407.

DOI:10.1056/NEJM199909303411407

PMID:10502596

Abstract

摘要

相似文献

Acute myeloid leukemia.

N Engl J Med. 1999 Sep 30;341(14):1051-62. doi: 10.1056/NEJM199909303411407.

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.

Ann Hematol. 2004;83 Suppl 1:S84-5. doi: 10.1007/s00277-004-0850-2.

[Individualized treatment of leukemia patients by monitoring of minimal residual disease (MRD) based on WT1 assay].

Rinsho Ketsueki. 1998 Feb;39(2):107-8.

AML1 and Pebp2: the gene for a transcription factor is involved in recurring translocations in human acute myeloid leukemia.

Jpn J Cancer Res. 1994 Dec;85(12):inside front cover.

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

Oncogene. 2001 Sep 10;20(40):5660-79. doi: 10.1038/sj.onc.1204593.

PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).

Genes Chromosomes Cancer. 2004 Aug;40(4):365-70. doi: 10.1002/gcc.20050.

Detection of ETV6/MDS1/Evi-1 chimeric transcripts in a patient with acute myelocytic leukemia and t(3;12)(q26;p13).

Int J Hematol. 2000 Jul;72(1):108-9.

[Cancer and fusion gene].

Tanpakushitsu Kakusan Koso. 1997 Sep;42(12):1978-90.

[Mechanism of leukemogenesis induced by AML 1-MTG 8].

Tanpakushitsu Kakusan Koso. 2000 Jan;45(1):26-32.

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).

Cancer Genet Cytogenet. 2006 Jul 15;168(2):172-4. doi: 10.1016/j.cancergencyto.2006.02.011.

引用本文的文献

Hypercholesterolemia and the role of lipid metabolism gene CES1 in immune infiltration promote central nervous system relapse in acute myeloid leukemia.

Front Immunol. 2025 Jul 23;16:1575472. doi: 10.3389/fimmu.2025.1575472. eCollection 2025.

Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) imparts selective leukemia cell death.

Cancer Metab. 2025 Jul 25;13(1):36. doi: 10.1186/s40170-025-00402-5.

Identification of Prognostic-Related Genes in Acute Myeloid Leukemia: A Study Based on TCGA Data Analysis.

Biochem Genet. 2025 Jul 23. doi: 10.1007/s10528-025-11193-1.

Computational investigation unveils pathogenic LIG3 non-synonymous mutations and therapeutic targets in acute myeloid leukemia.

PLoS One. 2025 Jun 10;20(6):e0320550. doi: 10.1371/journal.pone.0320550. eCollection 2025.

Distinguishing acute leukemia subtypes: The role of hsa_circ_0012152 and hsa_circ_0020093 in peripheral blood.

Oncol Lett. 2025 May 7;30(1):330. doi: 10.3892/ol.2025.15076. eCollection 2025 Jul.

Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism.

Cell Death Dis. 2025 Apr 23;16(1):331. doi: 10.1038/s41419-025-07653-6.

Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML.

Cell Commun Signal. 2025 Jan 28;23(1):53. doi: 10.1186/s12964-025-02046-w.

The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.

BMC Pharmacol Toxicol. 2025 Jan 20;26(1):10. doi: 10.1186/s40360-025-00839-w.

Trends in childhood cancer: Incidence and survival analysis over 45 years of SEER data.

PLoS One. 2025 Jan 3;20(1):e0314592. doi: 10.1371/journal.pone.0314592. eCollection 2025.

Gpmb-yolo: a lightweight model for efficient blood cell detection in medical imaging.

Health Inf Sci Syst. 2024 Mar 11;12(1):24. doi: 10.1007/s13755-024-00285-8. eCollection 2024 Dec.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Acute myeloid leukemia.

作者信息

Löwenberg B, Downing J R, Burnett A

机构信息

Department of Hematology, Erasmus University and University Hospital Rotterdam, The Netherlands.

出版信息

N Engl J Med. 1999 Sep 30;341(14):1051-62. doi: 10.1056/NEJM199909303411407.

DOI:10.1056/NEJM199909303411407

PMID:10502596

Abstract

摘要

相似文献

Acute myeloid leukemia.

N Engl J Med. 1999 Sep 30;341(14):1051-62. doi: 10.1056/NEJM199909303411407.

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461.

Ann Hematol. 2004;83 Suppl 1:S84-5. doi: 10.1007/s00277-004-0850-2.

[Individualized treatment of leukemia patients by monitoring of minimal residual disease (MRD) based on WT1 assay].

Rinsho Ketsueki. 1998 Feb;39(2):107-8.

AML1 and Pebp2: the gene for a transcription factor is involved in recurring translocations in human acute myeloid leukemia.

Jpn J Cancer Res. 1994 Dec;85(12):inside front cover.

AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

Oncogene. 2001 Sep 10;20(40):5660-79. doi: 10.1038/sj.onc.1204593.

PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).

Genes Chromosomes Cancer. 2004 Aug;40(4):365-70. doi: 10.1002/gcc.20050.

Detection of ETV6/MDS1/Evi-1 chimeric transcripts in a patient with acute myelocytic leukemia and t(3;12)(q26;p13).

Int J Hematol. 2000 Jul;72(1):108-9.

[Cancer and fusion gene].

Tanpakushitsu Kakusan Koso. 1997 Sep;42(12):1978-90.

[Mechanism of leukemogenesis induced by AML 1-MTG 8].

Tanpakushitsu Kakusan Koso. 2000 Jan;45(1):26-32.

Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).

Cancer Genet Cytogenet. 2006 Jul 15;168(2):172-4. doi: 10.1016/j.cancergencyto.2006.02.011.

引用本文的文献

Hypercholesterolemia and the role of lipid metabolism gene CES1 in immune infiltration promote central nervous system relapse in acute myeloid leukemia.

Front Immunol. 2025 Jul 23;16:1575472. doi: 10.3389/fimmu.2025.1575472. eCollection 2025.

Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) imparts selective leukemia cell death.

Cancer Metab. 2025 Jul 25;13(1):36. doi: 10.1186/s40170-025-00402-5.

Identification of Prognostic-Related Genes in Acute Myeloid Leukemia: A Study Based on TCGA Data Analysis.

Biochem Genet. 2025 Jul 23. doi: 10.1007/s10528-025-11193-1.

Computational investigation unveils pathogenic LIG3 non-synonymous mutations and therapeutic targets in acute myeloid leukemia.

PLoS One. 2025 Jun 10;20(6):e0320550. doi: 10.1371/journal.pone.0320550. eCollection 2025.

Distinguishing acute leukemia subtypes: The role of hsa_circ_0012152 and hsa_circ_0020093 in peripheral blood.

Oncol Lett. 2025 May 7;30(1):330. doi: 10.3892/ol.2025.15076. eCollection 2025 Jul.

Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism.

Cell Death Dis. 2025 Apr 23;16(1):331. doi: 10.1038/s41419-025-07653-6.

Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML.

Cell Commun Signal. 2025 Jan 28;23(1):53. doi: 10.1186/s12964-025-02046-w.

The clinical observation of none-promyelocytic AML patients inducted with idarubicin or daunorubicin included standard regimens: a tertiary care center experience.

BMC Pharmacol Toxicol. 2025 Jan 20;26(1):10. doi: 10.1186/s40360-025-00839-w.

Trends in childhood cancer: Incidence and survival analysis over 45 years of SEER data.

PLoS One. 2025 Jan 3;20(1):e0314592. doi: 10.1371/journal.pone.0314592. eCollection 2025.

Gpmb-yolo: a lightweight model for efficient blood cell detection in medical imaging.

Health Inf Sci Syst. 2024 Mar 11;12(1):24. doi: 10.1007/s13755-024-00285-8. eCollection 2024 Dec.